Jason Frankl

Jason Frankl founded and co-leads FTI Consulting’s Activism and M&A Solutions Practice, which works with companies that are the subject of shareholder activism and/or M&A activity in the development and implementation of strategies designed to maximize shareholder value. Mr. Frankl also advises management teams and boards of directors on how to proactively develop and implement defense strategies. Mr. Frankl has led teams of FTI Consulting professionals in connection with many high-profile shareholder activism and contested M&A situations.

Mr. Frankl is a nationally recognized expert in the areas of corporate governance, Nasdaq and NYSE regulation and securities trading.  He was named to the 2018, 2019, 2020 and 2021 National Association of Corporate Directors (“NACD”) Directorship 100 list, which recognizes the most influential leaders and advisors in corporate governance.  He has counseled hundreds of Nasdaq and NYSE listed companies on the application and strategies to achieve and regain compliance with U.S. exchange listing requirements, and many high-profile fund managers in making investment decisions.

Mr. Frankl has also led dozens of investigations and regulatory inquiries and has provided litigation support on behalf of publicly traded companies, boards of directors, board committees, banks and broker dealers involving Nasdaq, the NYSE, FINRA, CBOE, the SEC, the CFTC and the DOJ, in connection with securities trading matters (equities, options and physicals), activism and M&A defense, regulatory and disclosure requirements, fraud allegations, improper application of generally accepted accounting principles and corporate governance matters.

Prior to joining FTI Consulting, Mr. Frankl served as Counsel with the Nasdaq Stock Market where he conducted and/or was involved in over 1,000 hearings for issuers faced with the threat of delisting or denial of initial listing for failure to satisfy Nasdaq listing requirements.  Mr. Frankl also participated in the development and implementation of Nasdaq’s corporate governance rules and policies formulated in response to the Sarbanes-Oxley Act of 2002, including rules and policies pertaining to shareholder approval, voting rights and board independence.

In 2019, Mr. Frankl was appointed by Maryland Governor Larry Hogan to serve on the Board of Directors of the University of Maryland Medical System, a $4.5 billion medical system, where he also serves as the Chairman of the Audit & Compliance Committee, Chairman of the Investments Committee and as a member of the Executive Committee.   He was re-appointed by Governor Hogan for a second, five-year term in the spring of 2021.